Modifications to Previously Approved or Exempt Research

Scope
Mayo Clinic Human Research Protection Program
Research for which Mayo Clinic is the IRB of Record

Purpose
The purpose of this document is to describe the process and requirements Investigators use when modifications are made to IRB approved research activity.

Policy
- Modification of a research activity, during the period for which IRB approval has already been granted, must be submitted to the IRB and approved prior to initiation of the modification(s).
- Modifications must be submitted to the IRB within the following timelines. Refer to guidance: Reporting Timelines for IRB submission when Mayo Clinic is serving as the IRB of Record.
  - Changes necessary to eliminate apparent immediate hazards to the human subject may be initiated without prior IRB approval, and must be reported to the IRB within 5 working days.
  - Changes involving Significant New Information must be reported to the IRB within 5 working days.
  - All revised Investigator Brochures that do not meet the 5 day reporting requirement must be submitted within 30 calendar days.
  - Changes involving an increase in risk (newly identified or increase in severity) that does not meet the 5 day reporting requirement must be submitted within 30 calendar days.
  - Changes not involving risk or changes due to risks that have previously been reported to the Mayo Clinic IRB must be submitted within 60 calendar days.
  - Modifications not meeting the submission timeline must include a justification.
- Any modification to an exempt research project must be submitted to the IRB for review and re-determination of exemption status prior to initiating the changes to the research. In some circumstances, modifications to exempt research disqualify the research from the exempt status.
- Modifications to applications previously approved by a convened IRB may be reviewed using the expedited review process if the IRB finds:
  - The revision(s) do not pose an increased risk to subjects; and
  - The revision(s) constitute a minor change to previously approved research; and
  - Any added research activity falls within categories 1-7 of the Health and Human Services expedited review categories (45 CFR 46.110 - Categories of Research That May Be Reviewed by the Institutional Review Board (IRB) through an Expedited Review Procedure).
Modifications to applications previously approved by the expedited review process may be reviewed via expedited review if the IRB finds:

- The research continues to pose no more than minimal risk to subjects.
- Any added research activity falls within categories 1-7 of the HHS expedited review categories (45 CFR 46.110 - Categories of Research That May Be Reviewed by the Institutional Review Board (IRB) through an Expedited Review Procedure).

**Investigator Responsibilities**

The Investigator:

- Promptly (within 5 working days) reports to the IRB, using the IRB electronic Modification form, any research activity modifications which were made in order to avoid apparent immediate hazards to a subject and were implemented prior to IRB approval. The Modification will be titled ‘Urgent Action’ and include the Subject Notification form attachment.
- Promptly (within 5 working days) reports to the IRB any Significant New Information requiring urgent action using the IRB electronic Modification form. The Modification will be titled ‘Urgent Action’ and include the Subject Notification form attachment.
- Evaluates each proposed modification to the research activity to assess potential impact upon the risk/benefit ratio, severity or frequency of the previously described risk(s), safety, design, or execution of the research project.
- Revises research project documents accordingly. Describes each proposed modification and the justification for the change in the IRB electronic Modification form.
- Submits an IRB electronic Modification form (within the timelines listed above) to the IRB and attaches a revised protocol, consent form (if applicable), and other documents associated with the requested change. A Subject Notification Form is attached in all modifications involving an increase or significant change in risk.
- Re-consents or notifies subjects as directed by the IRB.
- Assures that any change to conflict of interest has been disclosed and reviewed by the Conflict of Interest Committee.

**IRB Responsibilities**

The IRB:

- Determines the level of review (expedited or convened IRB) required for the proposed modification(s).
- Reviews the proposed modification(s) in accordance with approval criteria and determines whether modifications(s) are consistent with ensuring the subject's continued protection.
- Reviews modifications initiated without prior IRB approval that eliminate apparent immediate hazards to the human subjects, and determines whether each change was consistent with ensuring the participant’s continued welfare.
Determined that any new significant findings arising from the review process, and possibly impacting the subject's willingness to continue participation are provided to the subject.

Determined if any new information resulting from the modification or from other sources necessitates an adjustment to the IRB's prior determination(s), such as inclusion of protected or vulnerable populations and findings regarding FDA-regulated products.

Determined if the proposed modifications to the research require revision of the consent document(s). If so, the IRB will ensure that revised consent documents accurately reflect the modifications.

Determined if the modifications warrant re-consenting or notification of subjects including those who have completed research interventions.

Considers whether the interval for continuing review as last determined by the IRB should be adjusted based on the modifications.

Determined whether the modifications to the research activity may require verification from sources other than the investigator that no material changes have occurred. See Verification of No Material Changes Since Previous IRB Review.

Notifies the Principal Investigator of IRB findings and determinations.

Policy Notes
NA

Related Procedure(s)
Expedited Review of Human Subjects Research
Exempt Human Subjects Research
Verification of No Material Changes since Previous IRB Review

Related Documents
Reporting Timelines for IRB Submission when Mayo Clinic is Serving as the IRB of Record (IRB10541)
Subject Notification Form (IRB10542)

Definitions
Significant New Information: Information that indicates a significant new serious risk or increased severity of known risk, or a safety issue which requires immediate action.

References
45 CFR 46.110 - Categories of Research That May Be Reviewed by the Institutional Review Board (IRB) through an Expedited Review Procedure
21 CFR 56.110 - Expedited review procedures for certain kinds of research involving no more than minimal risk, and for minor changes in approved research
**Owner**  
Pamela Kwon on behalf of Office for Human Research Protection

**Contact**  
Michelle Daiss, Angela Patterson

**Revision History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Synopsis of Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>6/1/2018</td>
<td>Updated to new template. IRB submission timelines added. Minor changes for clarification. Removed examples of major/minor modifications to be consistent with Reportable Event policy.</td>
</tr>
<tr>
<td>2/17/2016</td>
<td>Scheduled review – no changes</td>
</tr>
</tbody>
</table>